GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes

Diabetic Medicine

Volumn 23, Issue 8, 2006, Pages 834-838

  Castleden, H A J ^a   Shields, B ^a   Bingley, P J ^b   Williams, A J K ^b   Sampson, M ^c   Walker, M ^d   Gibson, J M ^e   McCarthy, M I ^f   Hitman, G A ^g   Levy, J C ^f   Hattersley, A T ^a   Vaidya, B ^a   Pearson, E R ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^d FREEMAN HOSPITAL   (United Kingdom)

^e HOPE HOSPITAL   (United Kingdom)

^f CHURCHILL HOSPITAL   (United Kingdom)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Familial inheritance; Glutamic acid decarboxylase antibodies; Latent autoimmune diabetes in adults; Type 1 diabetes; Type 2 diabetes

Indexed keywords

GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DESTRUCTION; FAMILY HISTORY; FEMALE; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT; PHENOTYPE; PREVALENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 2; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; MALE; MIDDLE AGED; PEDIGREE;

EID: 33746563454     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01915.x     Document Type: Article

References (20)

1. World Health Organization. Part 1: Diagnosis and Classification of Diabetes Mellitus. Report of a WHO Consultation. Geneva: World Health Organization 1999.
2. Tuomi T, Groop LC, Zimmer PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359-362.
3. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994; 11: 299-303.
4. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997; 350: 1288-1293.
5. Zimmet P, Turner R, McCarty D, Rowley M, Mackay I. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care, 1999; 22: B59-64.
6. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48: 150-157.
7. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004; 53: 3193-3200.
8. Irvine WJ, McCallum CJ, Gray RS, Duncan LJ. Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 1977; 1: 1025-1027.
9. Yu L, Cuthbertson DD, Eisenbarth GS, Krischer JP. Diabetes Prevention Trial 1: prevalence of GAD and ICA512 (IA-2) autoantibodies by relationship to proband. Ann NY Acad Sci 2002; 958: 254-258.
10. Douek IF, Gillespie KM, Bingley PJ, Gale EA. Diabetes in the parents of children with Type I diabetes. Diabetologia 2002; 45: 495-501.
11. Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997; 46: 1701-1710.
12. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003; 52: 1128-1136.
13. Takeda H, Kawasaki E, Shimizu I, Konoue E, Fujiyama M, Murao S et al. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care 2002; 25: 995-1001.
14. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995; 18: 1557-1565.
15. Borg H, Gottsater A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and β-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002; 51: 1754-1762.
16. Decochez K, Tits J, Coolens JL, Van Gaal L, Krzentowski G, Winnock F et al. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. Diabetes Care 2000; 23: 838-844.
17. Gatling W, Guzder RN, Turnbull JC, Budd S, Mullee MA. The Poole Diabetes Study: how many cases of Type 2 diabetes are diagnosed each year during normal health care in a defined community? Diabetes Res Clin Pract 2001; 53: 107-112.
18. Yudkin JS, Forrest RD, Jackson CA, Burnett SD, Gould MM. The prevalence of diabetes and impaired glucose tolerance in a British population. Diabetes Care 1993; 16: 1530.
19. Li H, Isomaa B, Taskinen MR, Groop L, Tuomi T. Consequences of a family history of type 1 and type 2 diabetes on the phenotype of patients with type 2 diabetes. Diabetes Care 2000; 23: 589-594.
20. Vauhkonen I, Niskanen L, Knip M, Ilonen J, Vanninen E, Kainulainen S et al. Impaired insulin secretion in non-diabetic offspring of probands with latent autoimmune diabetes mellitus in adults. Diabetologia 2000; 43: 69-78.